FDA Plays

[barefootrunner]

AMRN - Both SPPI and AMRN are excellent plays. I haven't looked at SPPI in several months, but have done a lot of research on AMRN. You have it right about ANCHOR and potential acquisition. Below is some DD I have posted on $heff's board:

AMRN - Much more upside to come.

Just doing some additional reading on AMRN and I think the potential is significant and the chances for a buyout are very good.

Some things to consider:

**GSK bought Reliant Pharmaceuticals in 2007 for $1.6bn primarily because of their interest in Lovaza - http://www.gsk.com/media/pressreleases/2007/2007_12_19_GSK1168.htm

**Lovaza already generates about $1bn in sales - http://www.reuters.com/article/2010/11/29/amarin-idUSLDE6AS08L20101129

**The MARINE trial data put AMR 101 on equal ground with Lovaza. Even though AMR 101 reduced TG levels by less than Lovaza, the baseline triglyceride level of patients in the pivotal Lovaza study was higher - around 800 mg/dl - http://www.thepharmaletter.com/file/100256/amarin-will-apply-for-approval-of-cholesterol-drug-candidate-amr101-earlier-on-strong-ph-iii-results.html

**The ANCHOR trial results are potentially game changing, as they address a much larger potential patient base - those patients with triglycerides of =200 and <500 mg/dL - http://www.thepharmaletter.com/file/100256/amarin-will-apply-for-approval-of-cholesterol-drug-candidate-amr101-earlier-on-strong-ph-iii-results.html

**The MARINE study was very effective in the statin-treated group:

Another surprise to me was the degree of TG-lowering efficacy in the statin-treated group, which exceeded the TG lowering in the non-statin treated group.

http://www.thepharmaletter.com/file/100256/amarin-will-apply-for-approval-of-cholesterol-drug-candidate-amr101-earlier-on-strong-ph-iii-results.html

Keep in mind that the ANCHOR study involves patients who are also taking a statin to lower cholesterol.

______________________________________________________

AMRN - More information and DD

It is important to keep in mind that Lovaza is only available for patients with VERY HIGH TG levels - > 500mg/dL. There is no prescription drug for patients with HIGH TG levels (200-499mg/dL).



The current treatment options can be found here:

http://www.webmd.com/cholesterol-management/tc/high-triglycerides-treatment-overview

So the question becomes whether doctors would be willing to prescribe a drug that addresses this segment of the population. If ANCHOR demonstrates superior efficacy and safety, I would think this would be a no brainer.